KemPharm (NASDAQ:KMPH) Rating Lowered to Sell at Zacks Investment Research

KemPharm (NASDAQ:KMPHGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “

A number of other research analysts also recently commented on the stock. StockNews.com assumed coverage on shares of KemPharm in a report on Thursday, March 31st. They issued a “hold” rating for the company. HC Wainwright raised shares of KemPharm from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $10.00 to $11.00 in a research note on Monday, January 31st.

Shares of NASDAQ:KMPH opened at $4.39 on Tuesday. KemPharm has a 12 month low of $4.00 and a 12 month high of $15.70. The company has a 50-day moving average price of $4.78 and a 200 day moving average price of $6.66.

KemPharm (NASDAQ:KMPHGet Rating) last announced its quarterly earnings results on Wednesday, March 30th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). KemPharm had a negative net margin of 0.60% and a negative return on equity of 0.28%. On average, sell-side analysts forecast that KemPharm will post -0.11 earnings per share for the current year.

Several large investors have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of KemPharm by 0.8% during the first quarter. BlackRock Inc. now owns 2,253,334 shares of the specialty pharmaceutical company’s stock worth $11,333,000 after acquiring an additional 17,792 shares during the period. Vanguard Group Inc. increased its position in shares of KemPharm by 2.2% during the first quarter. Vanguard Group Inc. now owns 1,516,912 shares of the specialty pharmaceutical company’s stock worth $7,630,000 after acquiring an additional 33,367 shares during the period. State Street Corp increased its position in shares of KemPharm by 2.4% during the first quarter. State Street Corp now owns 551,615 shares of the specialty pharmaceutical company’s stock worth $2,775,000 after acquiring an additional 12,798 shares during the period. Geode Capital Management LLC increased its position in shares of KemPharm by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 505,527 shares of the specialty pharmaceutical company’s stock worth $4,403,000 after acquiring an additional 16,795 shares during the period. Finally, Janney Montgomery Scott LLC increased its position in shares of KemPharm by 2.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 285,915 shares of the specialty pharmaceutical company’s stock worth $2,490,000 after acquiring an additional 6,475 shares during the period. 32.39% of the stock is currently owned by institutional investors and hedge funds.

KemPharm Company Profile (Get Rating)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Read More

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.